Financial

Powerful Medical Granted CPT Code for AI ECG Heart Attack Detection, Weeks After FDA De Novo Authorization of Queen of Hearts™

NEW YORK–(BUSINESS WIRE)– #AI–Powerful Medical, a leader in AI-driven cardiovascular diagnostics, today announced that the American Medical Association (AMA) CPT® Editorial Panel has established a new Category III CPT code, 1139T, for the noninvasive identification of ST-elevation myocardial infarction (STEMI), STEMI equivalents, and acute or subacute myocardial ischemia by assistive algorithmic analysis of the electrocardiogram (ECG). This is the service performed with Queen of Hearts™, which rec

RadNet, Inc. Announces Agreement to Acquire ONRAD, Inc.

RadNet, Inc. Announces Agreement to Acquire ONRAD, Inc.

RadNet, Inc. Announces Agreement to Acquire ONRAD, Inc.

RadNet, Inc. Announces Agreement to Acquire ONRAD, Inc.

Adds a radiology professional services platform offering teleradiology and in-hospital staffing for hospitals and health systemsEnables RadNet to seamlessly combine radiology professional services, AI-powered technology solutions and outpatient imaging operations into an integrated offering, transforming radiology workflows and ultimately improving patient careUniquely positions RadNet with an expanded offering to address the full range of care settings where imaging is performed inside and outside of hospitalsAcquisition adds to RadNet a capital-light, high-margin management services platform supporting more than 225 hospital facilities across 26 states with more than 130 contracted radiologistsONRAD is expected to add $190 million to $200 million of Revenue and $60 million to $65 million of Adjusted EBITDA(1) to RadNet in its first year of operation after closingRadNet and ONRAD management will host a conference call and webcast to discuss the transaction in more detail on Tuesday, October 27  LOS ANGELES, Oct. 26, 2026 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT) (“RadNet” or the “Company”), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services and a global developer of digital health solutions, today announced that it has entered into a definitive agreement to acquire ONRAD, Inc. (ONRAD).  ONRAD, through its more than 130 contracted radiologists, is a provider of teleradiology and in-hospital professional radiology staffing services for hospitals, health systems and other diagnostic imaging sites of care.  The transaction is expected to close in early 2027 and is subject to customary regulatory review and closing conditions.  Upon closing, ONRAD shareholders will receive a cash payment of $350 million and 5 million shares of RadNet, Inc. common stock, subject to customary adjustments.  In addition, an earnout of up to $210 million in value will be payable upon achievement of target EBITDA for 2027.  The earnout is payable in cash, RadNet common stock, or a combination thereof, at RadNet’s election. “This is the next step in building an imaging company with comprehensive solutions that brings technology, radiology professional services and imaging operations together to address some of healthcare’s most pressing challenges and needs,” said Dr. Howard Berger, President and CEO of RadNet.  “Connecting RadNet’s established AI-enabled digital health technology and imaging center operational expertise with ONRAD’s teleradiology and professional staffing solutions unites the capabilities needed to address the entire continuum of diagnostic imaging under one company.  The acquisition will enhance RadNet’s portfolio of solutions for hospitals and health systems, outpatient freestanding centers, urgent care facilities, freestanding emergency departments and physician offices.” Dr. Berger continued, “I welcome ONRAD’s executive team, its contracted radiologists and all other ONRAD team members into the RadNet family.  This transaction is a significant additional step in leading our industry forward and demonstrating the impact that a transformation to workflow solutions in diagnostic imaging can have in advancing early detection, population health and improved patient outcomes.” Through its contracted radiologists, ONRAD provides remote teleradiology final-read interpretations across many healthcare settings and in-hospital professional radiology staffing services, including interventional radiology, for hospitals and health systems.  Upon closing, ONRAD will become the foundation for RadNet’s third reportable operating segment, Radiology Professional Services.  With the addition of this third operating segment, RadNet becomes a comprehensive radiology services and solutions provider, addressing the imaging continuum across the full range of care settings, including hospitals, freestanding ambulatory outpatient centers, primary and specialty care physician offices and standalone urgent care and emergency department facilities. Strategic Rationale Connects three complementary businesses to provide comprehensive imaging solutions.  Combining RadNet outpatient imaging operations and DeepHealth AI-enabled digital health solutions with the ONRAD radiology professional services platform will bring together comprehensive expertise in the diagnostic imaging industry within one company.  Integrating these capabilities for customers and partners across all diagnostic imaging settings is expected to create efficiencies, improve patient care and lower costs in an unequaled approach.Expands RadNet into hospital-based radiology.  Hospitals and health systems account for more than 50% of U.S. diagnostic imaging volume.(2)  ONRAD will provide RadNet with an established platform to support in-hospital and remote professional radiology interpretation services while also expanding the RadNet offerings to its existing joint venture partners.Addresses growing market demand.  U.S. imaging demand growth is outpacing the supply of trained radiologists.  With ONRAD, RadNet will be positioned to further help address this gap by integrating AI-enabled technology with teleradiology and professional staffing services, creating opportunities to transform workflows, support case prioritization and better match interpretation capacity to demand.Adds a fast-growing, high-margin capital-light business.  ONRAD has demonstrated consistent annual revenue growth between 10% and 20% over the last several years with Adjusted EBITDA(1) margins exceeding 30%.  RadNet believes ONRAD will require very little capital to maintain and grow organically. “For 20 years, ONRAD has built long-standing relationships with hospitals and health systems delivering reliable, high-quality radiology coverage,” said Dave Engert, President and CEO of ONRAD.  “Joining RadNet not only gives us the scale, resources and technology to meet the growing needs of our current and prospective customers, but it also enables us to offer a unique imaging model that addresses the full continuum of care from outpatient imaging centers to the acute care environment.  The potential to further meet the ever-increasing demand for imaging services along with improving patient outcomes is what excites me most about our future together.” Conference Call and WebcastRadNet will host a conference call and webcast at 8:00 a.m. Eastern Time on Tuesday, October 27, 2026 to discuss the transaction in further detail.  To join by phone, dial 1-844-744-1280 for the U.S. and Canada and 1-412-564-6465 for international callers. A live webcast will be available at https://viavid.webcasts.com/starthere.jsp?ei=1780997&tp_key=417a069370. Robert W. Baird & Co. is serving as exclusive financial advisor to ONRAD, which is a portfolio company of Housatonic Partners.  About RadNet, Inc.RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.  RadNet has a network of owned and/or operated outpatient imaging centers.  RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia.  In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally.  Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 12,000 team members.  Learn more at radnet.com.    About ONRAD, Inc. ONRAD, Inc. is a leading radiology services company, delivering remote teleradiology final-read impressions and full-service radiology solutions for hospitals, radiology practices, outpatient clinics and imaging centers. Its spectrum of services includes reading remote and onsite diagnostic studies, interventional radiology, medical directorship, analytics, peer review, billing and quality oversight — all on the industry’s most advanced, integrated, AI-powered technology platform. ONRAD reads all modalities and has been Joint Commission accredited since its inception.  Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included in this press release that address activities, events or developments that RadNet expects, believes or anticipates will or may occur in the future are forward-looking statements. Terminology such as “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the transaction discussed herein, the expected timing and completion of such transaction, the anticipated benefits of such transaction, the potential earnout amount, the expected financial impact of the transaction on RadNet and other statements that are not historical facts. Forward-looking statements are based on current plans, estimates, expectations and assumptions as of the time they are made, are not guarantees of future performance and should not be relied on as predictions of future events, and there can be no assurance that such estimates, assumptions and expectations will prove to have been correct. These forward-looking statements involve risks and uncertainties, many of which are difficult to predict and are generally outside RadNet’s control, and other factors that could cause RadNet’s actual results or financial condition to differ materially from those expressed or implied by forward-looking statements, including (i) the risk that the conditions to the closing of the transaction, including required regulatory approvals, are not satisfied or waived on a timely basis or at all, and the risk that the transaction may not be completed on the anticipated terms, in the anticipated timeframe or at all, (ii) the occurrence of any event that could give rise to the termination of the definitive agreement for the transaction, (iii) the risks and costs associated with the transaction and integrating ONRAD and achieving the anticipated benefits of the transaction, (iv) potential disruption to the businesses of RadNet and ONRAD, including the ability to retain and hire key personnel and to maintain relationships with customers, suppliers and other business partners, as well as diversion of management’s time and attention from ordinary course business operations to completion of the transaction and integration matters, (v) potential litigation or regulatory action relating to the transaction, (vi) the effect of the transaction on RadNet’s indebtedness and leverage, credit ratings and liquidity, (vii) legislative, regulatory and economic developments, including in the healthcare industry, (viii) the effect of the announcement, pendency or completion of the transaction on the market price of RadNet’s common stock, and (ix) the other risks described under “Risk Factors” in RadNet’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. There may be additional risks, uncertainties and factors that we do not currently view as material or that are not necessarily known. Please read the Company’s filings with the SEC, which are available on the SEC’s website at https://www.sec.gov, for a discussion of risks and uncertainties that could cause actual results to differ from those in such forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements in this press release are qualified in their entirety by these cautionary statements. Except as required by law, RadNet undertakes no obligation and does not intend to update or revise any forward-looking statements, whether as a result of new information, future results or otherwise.  No Offer or Solicitation This press release is for informational purposes only and shall not constitute or form part of, an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities, in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.  References (1)The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation.  Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taken place during the period.     Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt.  Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.   The Company’s guidance or target for ONRAD’s addition to Adjusted EBITDA is also a non-GAAP financial measure that excludes or otherwise has been adjusted for non-GAAP adjustment items from the Company’s GAAP financial statements. When the Company provides guidance or its target for ONRAD’s addition to Adjusted EBITDA, it does not provide a reconciliation of the GAAP measure as it is unable to predict with a reasonable degree of certainty the actual impact of the non-GAAP adjustment items. By their very nature, non-GAAP adjustment items are difficult to anticipate with precision because they are generally associated with unexpected and unplanned events that impact the Company and its financial results. Therefore, the Company is unable to provide a reconciliation of these measures without unreasonable efforts.   (2)Based on a Signify analysis.    RadNet Media Contacts  Jane Mazur  Senior Vice President, Corporate Communications  +1 585-355-5978  jane.mazur@radnet.com     Mark Stolper Executive Vice President and Chief Financial Officer +1 310-445-2800 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/05e518ec-4d83-4fcc-a69f-3e80e67f4d30

Parasol Med Tech Secures $2.75M to Improve Stroke Prevention in Atrial Fibrillation

Parasol Med Tech, a Chicago-based medical device company, today announced that it has closed an oversubscribed $2.75 million pre-seed funding round. The round included participation from Harper Court Ventures, UChicago Medicine Ventures, a venture investment vehicle of the University of Chicago Medical Center, and Cardiovascular Innovation Ventures, the venture arm […]

Elucid Statement on Heartflow Lawsuit: Reaffirms Mission, Confidence in Its Technology, and Commitment to Patients and Physicians

BOSTON–(BUSINESS WIRE)–Elucid Bioimaging Inc. (“Elucid”) today reaffirmed its commitment to advancing its mission – the prediction and personalization of the prevention of heart attack and stroke – and its confidence in the technology and intellectual property behind its products. Elucid is aware of a lawsuit filed by Heartflow, Inc., on October 22, 2026. Elucid will respond to and defend against the claims in the lawsuit through the appropriate legal channels. “Elucid was founded to help phy

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

MINNEAPOLIS, Oct. 22, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2026 financial and operating results after market close on Thursday, Nov. 5, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1- 877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time. About CVRx, Inc.CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. Investor Contact:Mark Klausner ICR Healthcare443-213-0501ir@cvrx.com Media Contact:Emily Meyers CVRx, Inc. 763-416-2853emeyers@cvrx.com

EBR Systems Appoints Robert Canby, MD, as Chief Medical Officer

SUNNYVALE, Calif.–(BUSINESS WIRE)–EBR Systems, Inc., developer of the world’s only left ventricular endocardial pacing (LVEP) system for heart failure, announces the appointment of Robert C. Canby, MD, as Chief Medical Officer. Key Highlights Robert Canby, MD, appointed Chief Medical Officer is a board-certified cardiac electrophysiologist who brings extensive experience across clinical practice, physician education, cardiovascular research, and medical device innovation. Dr. Canby practices

Route 92 Medical Announces $100 Million Corporate Debt Facility

Financing Strengthens Balance Sheet and Supports Continued Product Innovation and Commercial GrowthWEST JORDAN, Utah, Oct. 20, 2026 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced that it has entered into a $100 million senior secured debt facility with Trinity Capital Inc., a leading provider of flexible capital solutions for innovative, growth-stage to lower middle market companies across the United States and Europe. Route 92 Medical has developed an integrated neurovascular platform that combines access, delivery, and control in a cohesive system, enabling clinicians to reach treatment sites reliably and efficiently. Tenzing® delivery catheters are foundational to the Route 92 platform, enabling atraumatic, precise, and controlled navigation through complex neurovascular anatomy. All Route 92 access and aspiration catheters are powered by custom-sized Tenzing delivery catheters and are size-matched to the vessels they access. Route 92 has also developed Monopoint®, the only mono-axial neurovascular platform, featuring a streamlined telescoping design that advances from a single point of control to simplify neurovascular intervention. “Entering into this financing with Trinity Capital is an important step for Route 92 as we execute on our growth strategy,” said Raj Denhoy, Chief Financial Officer of Route 92 Medical. “This facility gives us additional financial flexibility to support the strong demand we are seeing for our products. Trinity’s understanding of the medical technology sector and their confidence in our technology, commercial momentum, and long-term vision make them a valuable partner as we work to transform the treatment of neurovascular disease.” Route 92’s portfolio of advanced neurovascular catheters includes the FreeClimb® 46, 54, 70, and 88 systems, as well as the HiPoint® 70 and 88 systems, which feature Monopoint. HiPoint 88 is the first super-bore aspiration system with FDA clearance for direct aspiration of large vessel occlusions (LVOs) in acute ischemic stroke. The most recent addition, FreeClimb 46 with Tenzing 4, offers a differentiated tool for navigating more distal and smaller anatomies. Route 92’s catheters and systems are covered by a portfolio of more than 200 issued patents in the U.S. and international jurisdictions. About Route 92 Medical, Inc.Route 92 Medical is on a mission to improve outcomes for patients undergoing neurovascular intervention through cutting-edge engineering, innovative product design, and revolutionary procedural change. Founded by physicians, the company collaborates with leading neurovascular clinicians to solve the biggest challenges in neurointervention and deliver meaningful, differentiated solutions that promote clinical success. For more information, visit www.r92m.com or follow the company on LinkedIn. CONTACT: Contacts:

For media:
Gwen Gordon
Gwen@gwengordonpr.com

Conavi Medical Announces New Grants of Stock Options

TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it has granted an aggregate of 1,600,000 stock options to purchase common shares of the Company to officers of the Company pursuant to the Company’s Omnibus Equity Incentive Plan (the “Plan”). The stock options are exercisable at a price of C$0.20 per common share and have a term of ten years from the date of grant. The options vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in equal monthly instalments over the subsequent 36 months, subject to the terms of the Plan. The grant of these stock options remains subject to the approval of the TSX Venture Exchange. About Conavi Medical Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented hybrid imaging system is the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries. The hybrid imaging system has 510(k) clearance from the U.S. Food and Drug Administration. For more information, visit http://www.conavi.com/. Forward looking information This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the commercialization and commercial launch of Conavi’s hybrid imaging system and the timing thereof, the sufficiency of Conavi’s resources to achieve such commercial launch, the global market opportunity for coronary intravascular imaging (including for IVUS and OCT), the continued growth in adoption of and in the clinical validation and guideline support for intravascular imaging and the ability of Conavi’s hybrid imaging system to meet market needs. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the annual information form of the Company dated February 26, 2026 (available on the Company’s profile at www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Contact Mark Quick, Chief Financial Officer | 416-483-0100Christina Cameron, Investor Relations | 416-483-0100 ext. 121 | IR@conavi.com

Detlef Schumann

Groundbreaking therapy for advanced heart failure: Repairon Strengthens Executive Leadership with Appointment of Detlef Schumann, Ph.D. as Chief Operating Officer

Biotech executive brings global leadership and operations experience to speed clinical development, expand operations, and carry out strategic growth plans.GÖTTINGEN, Germany and PROVIDENCE, R.I., Oct. 19, 2026 (GLOBE NEWSWIRE) — Repairon, a biotechnology company developing regenerative cardiac therapies, today announced the appointment of Detlef Schumann, Ph.D. as Chief Operating Officer. Schumann will report to CEO Lothar Germeroth, Ph.D. and oversee global operations and strategic growth initiatives. Dr. Schumann brings extensive executive leadership experience across biotechnology, pharmaceuticals, and medical devices, combining deep scientific and technical expertise in cell therapy, advanced therapy medicinal products (ATMPs), regenerative medicine, and medical devices with a strong track record in operational excellence, organizational development, GMP manufacturing, automation, strategic partnerships, and M&A. He has developed and implemented international growth strategies, with particular expertise in EMEA, Japan and Singapore. As CEO of TETEC Tissue Engineering Technologies AG, he established sustained growth through the restructuring and scaling of GMP-compliant ATMP manufacturing operations and highly specialized CDMO services. He served as Managing Director of CeGaT GmbH, Vice President for Technology Innovation at B. Braun Aesculap, and held senior research and business development positions at DSM Biomedical. Dr. Schumann holds a degree in pharmacy and a doctorate in regenerative medicine and pharmaceutical technology from the University of Regensburg, Germany. His academic research experience includes postdoctoral fellowships at MIT/Harvard and the National University of Singapore. Repairon’s CEO, Lothar Germeroth, remarked that “the addition of Detlef Schumann to our senior leadership team is crucial for the company’s forthcoming expansion. His experience and leadership will have a direct impact on scaling up production, executing pivotal clinical trials, increasing focus on Far East markets, and managing and growing our revenue-generating activities in Germany. Fueled by the positive clinical outcomes of our Phase I-II clinical study, as the first company to demonstrate the restoration of heart muscle in ischemic advanced heart failure patients, we look forward to developing Repairon’s BioVAT product. “Contributing to the clinical, regulatory, and commercial development of one of the most significant tissue engineering technologies in cardiovascular medicine is a fabulous opportunity and a significant responsibility,” said Detlef Schumann. “I look forward to applying all my skills, experience, and energy to build Repairon and develop BioVAT for the benefit of millions of advanced heart failure patients worldwide.”     High medical need in advanced heart failure: Approximately 5% of the global population suffers from chronic heart failure of any severity, and it remains one of the most common causes of death. In the US, heart failure represents the most common cause of hospitalization and mortality in the senior population, and over 6 million people are affected. As heart failure progresses to advanced stages, patients experience weakness with discomfort during all physical activities and at rest, sometimes even requiring constant bed rest. For these severely ill patients, the only treatment options currently available are mechanical pump devices or heart transplantation. About Repairon: Repairon GmbH is a German biotech company based in Göttingen, Germany, focused on developing regenerative cell therapies for cardiac medicine. The company was founded in 2014 based on research by Wolfram-Hubertus Zimmermann, MD and his team at the University Medical Center Goettingen, who have developed several tissue engineering technologies with proven applicability for organ repair and drug development. Repairon’s lead therapeutic candidate, the human engineered heart muscle patch, is currently being evaluated in the BioVAT-HF Phase 2 clinical trial as a biological ventricular assist tissue (BioVAT) for end-stage heart failure. Company contact:Dr. Lothar GermerothRepairon GmbH37079 Göttingen – GermanyEmail: germeroth@repairon.deUS contact:Frank AhmannRepairon USAProvidence, RI Email: f.ahmann@repairon.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/64985d27-8653-4e2b-a6b9-38b0d3a46954

Precision Neuroscience™ Appoints Nevro Founder Konstantinos Alataris as President and Katherine Neuenfeldt as Senior Vice President, Commercial Strategies

NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) — Precision Neuroscience Corporation (Precision), a brain–computer interface (BCI) company, today announced that Konstantinos Alataris, Ph.D., founder and former chief executive officer of Nevro, has joined as president, and Katherine Neuenfeldt, who led the U.S. launch and market access strategy for Nevro’s Senza spinal cord stimulation system, has joined as senior vice president, commercial strategies. Following Precision’s $250 million Series D financing, the two executives will advance the company’s BCI toward commercialization, drawing on their experience developing, launching, and securing reimbursement for implantable medical devices. “Precision has established a leading position in BCI technology, and our recent financing gives us the resources to take the next step,” said Michael Mager, co-founder and CEO of Precision. “Bringing a new Class III medical device to market takes more than technical skill and capital. We have to be able to build products that physicians can rely on and that insurers will pay for. Konstantinos and Katherine have done exactly that with implantable devices in the nervous system. Their experience will be critical as we move from demonstrating what our technology can do to making it available to patients.” Alataris has served on Precision’s board of directors since May 2025 and will continue in that role alongside his responsibilities as president. Alataris founded Nevro in 2006 and led the development and commercial launch of its high-frequency spinal cord stimulation technology for chronic pain. Nevro received European CE marking for its spinal cord stimulation system in 2010, went public on the New York Stock Exchange in 2014, and received FDA approval for the system in 2015, achieving a multi-billion dollar market capitalization. Beyond Nevro, Alataris has held executive and board roles across medical device, biotechnology, and pharmaceutical companies, including serving as president and CEO of Zosano Pharma, co-founding Nēsos, and chairing the scientific advisory board of Iota Biosciences until its acquisition by Astellas Pharma. He currently serves on the boards of Oryzon Genomics SA (BME: ORY), a clinical-stage biopharmaceutical company developing epigenetic therapies for cancer and central nervous system (CNS) disorders, and Delsona Therapeutics, a Columbia University spinout developing focused ultrasound therapeutics. He is also a partner and co-chairman at Forepont Capital, a New York-based private equity firm. Previously, he was a vice president at healthcare investment firm Bay City Capital. “Precision has demonstrated that it is possible to achieve high-performance neural control without penetrating the brain — something many believed couldn’t be done. That is a testament to the vision and dedication of co-founders Michael Mager and Ben Rapoport and the entire team,” Alataris said. “The next chapter is turning today’s breakthroughs into everyday medicine: reliable, repeatable, exceptional performance that neurosurgeons and patients can depend on, case after case. That is the work I wanted to help lead. Moving from the board into an operating role was a natural progression, an opportunity to roll up my sleeves and help bring the promise of Precision’s technology to patients.” Neuenfeldt leads Precision’s commercial strategy and market access efforts. She joined Nevro when the company had roughly 60 employees and led marketing for its successful 2015 U.S. launch of HF10 therapy. Later, as vice president of market access, she built and led a 40-person commercial team spanning national accounts, pricing and contracting, analytics, patient access, and reimbursement. Her team drove insurance coverage, adoption, and market differentiation for Nevro’s products globally. She previously spent six years at Medtronic Cardiovascular, where she led the U.S. launch of its flagship Endurant AAA stent graft, and most recently served as senior vice president of commercial strategies at Presidio Medical. “Joining Precision allows me to bring my experience launching disruptive medical devices backed by rigorous clinical evidence to a mission that is deeply personal to me,” Neuenfeldt said. “A device can be safe and effective, and a physician can want to use it, but if payers don’t cover it, patients won’t have access. For BCI technologies to reach people living with ALS, spinal cord injury, and brainstem stroke, we need to lay the groundwork for insurance coverage now, including generating clinical evidence that demonstrates meaningful benefits for patients.” The appointments follow Precision’s $250 million Series D financing, which brought its total capital raised to $430 million. Since its founding in 2021, Precision has built the largest clinical footprint in BCI, with more than 100 patient procedures across 18 medical institutions. The company has demonstrated high-resolution neural recording across 4,096 electrodes and real-time decoding of intended movement, received FDA clearance for its Layer 7™ cortical surface array, and published peer-reviewed research, including in Nature Biomedical Engineering. It has also established a commercial partnership with Medtronic and built a wholly owned MEMS manufacturing facility in Texas. About Precision NeurosciencePrecision Neuroscience is developing breakthrough treatments and technology for millions of people worldwide. The company is building the only brain–computer interface designed to be minimally invasive, safely removable, and high-bandwidth. To learn more about how Precision is connecting human and artificial intelligence, visit www.precisionneuro.io. Media Contactmedia@precisionneuro.io